Researchers sought to determine whether different doses of ponatinib would have benefit for patients with resistant chronic-phase chronic myeloid leukemia.
Patients may not have much information on chronic myeloid leukemia, and some may have a number of misunderstandings surrounding the condition. As a health care professional, what are some of these myths you can correct to better educate patients?
Researchers sought to determine whether MRD would improve after fixed-duration treatment with venetoclax and obinutuzumab therapy in patients with CLL.
Researchers sought to determine whether analyzing mutations after diagnosis with juvenile myelomonocytic leukemia would aid patient stratification and treatment personalization.
Researchers sought to determine whether T cell replete HLA haploidentical hematopoietic stem cell transplantation with low-dose anti-thymocyte globulin would improve outcomes in patients with BCP-ALL.
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Researchers sought to determine the accuracy of established cardiovascular assessment tools in predicting risk of CV events in patients with CML receiving TKIs.
Researchers sought to determine whether mutations in the PTPN11 gene would be a prognostic factor for poor survival in patients with acute myeloid leukemia.
Differentiation syndrome is a potentially severe complication in AML, although prompt management is usually effective and rarely requires cessation of targeted therapy.
Researchers sought to determine whether the ALFA decision tool would be able to determine the prognosis for older patients with AML treated with intensive chemotherapy.
Tyrosine kinase inhibitors have improved survival outcomes for patients with CML, but these agents also have a greater risk for adverse cardiovascular events.
Researchers sought to determine whether the antisense oligonucleotide oblimersen can be added safely to conventional chemotherapy for older patients with AML.
Researchers sought to determine whether for CD200 expression in leukemia stem cells would be associated with acute myeloid leukemia and therefore be a target for treatment.
Researchers seek to characterize adherence trajectories, determine how side effects or financial status influence adherence, assess how adherence effects clinical outcomes, and explore unique patient perspectives.
Acute myeloid leukemia (AML) progresses more rapidly than other forms of leukemia. As such, if you or your patient are concerned they may have AML it is important to educate them on the symptoms and risk factors of the disease, as well as how to detect it and what treatments it could entail.
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.
